Diabetes: how to manage cardiovascular risk in secondary prevention patients

Diabetes: how to manage cardiovascular risk in secondary prevention patients

Atherosclerotic cardiovascular disease (ASCVD) commonly affects people with type 2 diabetes (T2D). Historically, traditional cardiovascular (CV) risk-lowering therapies in patients with T2D and ASCVD have included antiplatelet agents, blood pressure-lowering therapies, lipid-lowering therapies and h...

Full description

Bibliographic Details
Main Authors:	Sarah L Anderson, Joel C Marrs
Format:	Article
Language:	English
Published:	BioExcel Publishing Ltd 2022-06-01
Series:	Drugs in Context
Subjects:	atherosclerotic cardiovascular disease cardiovascular disease diabetes glp1 receptor agonists sglt2 inhibitors type 2 diabetes
Online Access:	https://www.drugsincontext.com/diabetes-how-to-manage-cardiovascular-risk-in-secondary-prevention-patients

Similar Items

The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies
by: Devinder S. Dhindsa, et al.
Published: (2018-11-01)

Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC
by: Zachary Bloomgarden, et al.
Published: (2020-03-01)

Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
by: Almudena Castro Conde, et al.
Published: (2023-06-01)

Newer Diabetes Management Options and Physical Fitness to Promote Cardiovascular Benefits
by: Eric Nylén
Published: (2022-08-01)

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
by: Schernthaner G, et al.
Published: (2017-12-01)

Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors
by: Cosmin Mihai Vesa, et al.
Published: (2020-05-01)

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
by: Takayuki Yamada, et al.
Published: (2021-01-01)

Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials
by: Lisa Ludwig, et al.
Published: (2020-05-01)

A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease
by: Lyndon Marc Evans, et al.
Published: (2021-07-01)

The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States
by: Wayne Weng, et al.
Published: (2019-07-01)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
by: Stefan D. Anker
Published: (2019-12-01)

The role of novel antihyperglycaemic agents in the treatment of Type 2 diabetes: From glycaemic control to cardiovascular protection
by: Žunić Tatjana, et al.
Published: (2020-01-01)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
by: Yuta Suzuki, et al.
Published: (2022-05-01)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
by: Charlotte C. van Ruiten, et al.
Published: (2022-04-01)

SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins
by: Awadhesh K Singh, et al.
Published: (2019-01-01)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
by: Aurélie Pahud de Mortanges, et al.
Published: (2021-11-01)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
by: Lixin Du, et al.
Published: (2022-08-01)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
by: Dario Giugliano, et al.
Published: (2021-10-01)

Heart failure in diabetes: From an increased risk to a treatment target
by: Eberhard Standl
Published: (2018-11-01)

Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches
by: Jing Xu, et al.
Published: (2021-12-01)

Cardiovascular outcomes of antidiabetic drugs
by: Ranjit Kumar Nath, et al.
Published: (2021-03-01)

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
by: Yushmanova Irina, et al.
Published: (2011-03-01)

Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study
by: Devine S. Frundi, et al.
Published: (2022-07-01)

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
by: Andrei C. Sposito, et al.
Published: (2018-12-01)

NEW APPROACHES IN THE TREATMENT OF TYPE 2 DIABETES - TRANSITION FROM GLUCOSE-CENTRED TO PATIENT-CENTRED MODEL
by: Antoaneta Tsvetkova, et al.
Published: (2021-08-01)

Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
by: Katherine G. Young, et al.
Published: (2023-11-01)

Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD)
by: André J. Scheen
Published: (2023-07-01)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
by: Mei Qiu, et al.
Published: (2021-12-01)

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
by: Honghong Zou, et al.
Published: (2017-05-01)

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
by: Ofri Mosenzon, et al.
Published: (2021-07-01)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
by: Dimitrios Patoulias, et al.
Published: (2021-01-01)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
by: Lixin Du, et al.
Published: (2022-09-01)

Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin
by: Panagiotis Theofilis, et al.
Published: (2022-10-01)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: Heeyoung Lee, et al.
Published: (2021-09-01)

La terapia del diabete nel paziente nefropatico
by: Edoardo Mannucci, et al.
Published: (2015-06-01)

SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Zinan Zhao, et al.
Published: (2022-04-01)

Gliflozins and their beneficial hypoglycaemic effect profile and prevention of cardiovascular complications in patients treated for type II diabetes mellitus
by: Natalia Sobańska, et al.
Published: (2023-02-01)

Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease
by: André J. Scheen
Published: (2024-04-01)

Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide
by: Charlotte C. van Ruiten, et al.
Published: (2022-05-01)

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
by: Schernthaner G, et al.
Published: (2017-01-01)